BioCentury
ARTICLE | Clinical News

Autolymphocyte therapy: To start patient accrual in the fourth quarter under a Treatment IND in patients with stage IV disease who did not participate in the co

September 25, 1995 7:00 AM UTC

CLTX is in the process of merging with CYTOGEN Corp. (Princeton, N.J.) (see page B2). ...